Engineered human mesenchymal stem cells for neuroblastoma therapeutics

Area of Science:

• Paediatric Oncology
• Cell and Gene Therapy
• Cancer Therapeutics

Background:

• Drug-resistant neuroblastoma presents a significant challenge in pediatric cancer treatment.
• Novel, less toxic therapies are crucial to improve survival rates and minimize side effects of conventional treatments.
• Mesenchymal stem cells (MSCs) are promising for cell and gene therapy due to their tumor-homing capabilities.

Purpose of the Study:

• To evaluate the efficacy of MSCs engineered to express tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) against neuroblastoma.
• To determine if TRAIL-engineered MSCs can induce neuroblastoma cell death in vitro.
• To assess the in vivo migration of TRAIL-engineered MSCs to tumor sites and their impact on neuroblastoma growth in xenotransplantation models.

Main Methods:

• In vitro testing of TRAIL-loaded MSCs against classic and primary neuroblastoma cell lines.
• In vivo experiments involving the intraperitoneal injection of TRAIL-engineered MSCs into neuroblastoma-bearing mice.
• Assessment of MSC migration to tumor sites and evaluation of tumor growth reduction.

Main Results:

• TRAIL-loaded MSCs demonstrated the ability to kill neuroblastoma cell lines expressing death receptors in vitro.
• In vivo, TRAIL-engineered MSCs successfully migrated to neuroblastoma tumor sites.
• Despite migration, TRAIL-engineered MSCs did not significantly alter the progression of neuroblastoma in vivo.

Conclusions:

• Mesenchymal stem cells engineered with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) show in vitro efficacy against neuroblastoma.
• While MSCs can be engineered for drug delivery and migrate to tumors, TRAIL is not an effective therapeutic payload for neuroblastoma.
• Further research is needed to identify more potent biopharmaceuticals for MSC-mediated drug delivery in neuroblastoma treatment.